The Locus Coeruleus: Essential for Maintaining Cognitive Function and the Aging Brain

Trends in Cognitive Sciences

Volumn 20, Issue 3, 2016, Pages 214-226

  Mather, Mara ^a   Harley, Carolyn W ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN; NEURODEGENERATIVE DISEASES; PATHOLOGY;

ALZHEIMER'S DISEASE; COGNITIVE ABILITY; COGNITIVE AGING; COGNITIVE DECLINE; COGNITIVE FUNCTIONS; COGNITIVE RESERVES; HIGH EXPOSURES; TAU PATHOLOGY;

NEURONS;

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NEUROMELANIN; NORADRENALIN; TAU PROTEIN;

ADULTHOOD; ALZHEIMER DISEASE; COGNITION; COGNITIVE AGING; COGNITIVE RESERVE; HUMAN; LOCUS CERULEUS; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; REVIEW; AGING; ANIMAL; CYTOLOGY; METABOLISM; NERVE CELL; PHYSIOLOGY;

AGING; ANIMALS; COGNITION; HUMANS; LOCUS COERULEUS; NEURONS; NOREPINEPHRINE;

EID: 84958231684     PISSN: 13646613     EISSN: 1879307X     Source Type: Journal    
DOI: 10.1016/j.tics.2016.01.001     Document Type: Review

References (132)

1. Brezina V. Beyond the wiring diagram: signalling through complex neuromodulator networks. Phil. Trans. R. Soc. B Biol. Sci. 2010, 365:2363-2374.
2. Marder E. Neuromodulation of neuronal circuits: back to the future. Neuron 2012, 76:1-11.
3. Sara S.J. The locus coeruleus and noradrenergic modulation of cognition. Nat. Rev. Neurosci. 2009, 10:211-223.
4. Braak H., Del Tredici K. Neuroanatomy and Pathology of Sporadic Alzheimer's Disease 2015, Springer International Publishing.
5. Mravec B., et al. Locus (coeruleus) minoris resistentiae in pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 2014, 11:992-1001.
6. Wilson R.S., et al. Neural reserve, neuronal density in the locus ceruleus, and cognitive decline. Neurology 2013, 80:1202-1208.
7. Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Neurol. 2012, 11:1006-1012.
8. Robertson I.H. A noradrenergic theory of cognitive reserve: implications for Alzheimer's disease. Neurobiol. Aging 2013, 34:298-308.
9. Feinstein D.L., et al. Noradrenergic regulation of inflammatory gene expression in brain. Neurochem. Int. 2002, 41:357-365.
10. Heneka M.T., et al. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:6058-6063.
11. German D., et al. The human locus coeruleus: computer reconstruction of cellular distribution. J. Neurosci. 1988, 8:1776-1788.
12. Lohr J.B., Jeste D.V. Locus ceruleus morphometry in aging and schizophrenia. Acta Psychiatr. Scand. 1988, 77:689-697.
13. Marcyniuk B., et al. The topography of nerve cell loss from the locus caeruleus in elderly persons. Neurobiol. Aging 1989, 10:5-9.
14. Tomlinson B., et al. Cell loss in the locus coeruleus in senile dementia of Alzheimer type. J. Neurol. Sci. 1981, 49:419-428.
15. Vijayashankar N., Brody H. Quantitative study of the pigmented neurons in the nuclei locus coeruleus and subcoeruleus in man as related to aging. J. Neuropathol. Exp. Neurol. 1979, 38:490-497.
16. Chan-Palay V., Asan E. Quantitation of catecholamine neurons in the locus coeruleus in human brains of normal young and older adults and in depression. J. Comp. Neurol. 1989, 287:357-372.
17. Manaye K.F., et al. Locus-coeruleus cell loss in the aging human brain: A nonrandom process. J. Comp. Neurol. 1995, 358:79-87.
18. Kubis N., et al. Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain 2000, 123:366-373.
19. Ohm T., et al. Unbiased estimation of neuronal numbers in the human nucleus coeruleus during aging. Neurobiol. Aging 1997, 18:393-399.
20. Mouton P.R., et al. Absolute number and size of pigmented locus coeruleus neurons in young and aged individuals. J. Chem. Neuroanat. 1994, 7:185-190.
21. Braak H., et al. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 2011, 70:960-969.
22. Nelson P.T., et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 2012, 71:362.
23. Matthews K.L., et al. Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol. Psychiatry 2002, 51:407-416.
24. Braak H., Del Tredici K. Amyloid-β may be released from non-junctional varicosities of axons generated from abnormal tau-containing brainstem nuclei in sporadic Alzheimer's disease: a hypothesis. Acta Neuropathol. 2013, 126:303-306.
25. Riley K.P., et al. Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study. Neurobiol. Aging 2005, 26:341-347.
26. Clewett D., et al. Neuromelanin marks the spot: Identifying a locus coeruleus biomarker of cognitive reserve in healthy aging. Neurobiol. Aging 2016, 37:117-126.
27. Takahashi J., et al. Detection of changes in the locus coeruleus in patients with mild cognitive impairment and Alzheimer's disease: High-resolution fast spin-echo T1-weighted imaging. Geriatr. Gerontol. Int. 2015, 15:334-340.
28. Wakamatsu K., et al. Norepinephrine and its metabolites are involved in the synthesis of neuromelanin derived from the locus coeruleus. J. Neurochem. 2015, 135:768-777.
29. Zucca F.A., et al. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. Prog. Neurobiol. 2015, Published online October 9, 2015. 10.1016/j.pneurobio.2015.09.012.
30. Shibata E., et al. Age-related changes in locus ceruleus on neuromelanin magnetic resonance imaging at 3 Tesla. Magn. Reson. Med. Sci. 2006, 5:197-200.
31. Keren N.I., et al. Histologic validation of locus coeruleus MRI contrast in post-mortem tissue. Neuroimage 2015, 113:235-245.
32. Braun D., et al. Noradrenergic regulation of glial activation: molecular mechanisms and therapeutic implications. Curr. Neuropharmacol. 2014, 12:342.
33. Mei Y., et al. Aging-associated formaldehyde-induced norepinephrine deficiency contributes to age-related memory decline. Aging Cell 2015, 14:659-668.
34. Luo Y., et al. Reversal of aging-related emotional memory deficits by norepinephrine via regulating the stability of surface AMPA receptors. Aging Cell 2015, 14:170-179.
35. Kalinin S., et al. The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease. Neurobiol. Aging 2012, 33:1651-1663.
36. Kummer M.P., et al. Ear2 deletion causes early memory and learning deficits in APP/PS1 mice. J. Neurosci. 2014, 34:8845-8854.
37. Liu X., et al. Norepinephrine protects against amyloid-β toxicity via TrkB. J. Alzheimers Dis. 2015, 44:251-260.
38. Jardanhazi-Kurutz D., et al. Distinct adrenergic system changes and neuroinflammation in response to induced locus ceruleus degeneration in APP/PS1 transgenic mice. Neuroscience 2011, 176:396-407.
39. Counts S.E., Mufson E.J. Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity. J. Neurochem. 2010, 113:649-660.
40. Li S., et al. Environmental novelty activates β2-adrenergic signaling to prevent the impairment of hippocampal LTP by Aβ oligomers. Neuron 2013, 77:929-941.
41. Yang J.H., et al. Norepinephrine differentially modulates the innate inflammatory response provoked by amyloid-β peptide via action at β-adrenoceptors and activation of cAMP/PKA pathway in human THP-1 macrophages. Exp. Neurol. 2012, 236:199-206.
42. Mather M., et al. Norepinephrine ignites local hot spots of neuronal excitation: how arousal amplifies selectivity in perception and memory. Behav. Brain Sci. 2015, Published online July 1, 2015. 10.1017/S0140525X15000667.
43. Joas E., et al. Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years. Hypertension 2012, 59:796-801.
44. Ross J.A., et al. Locus coeruleus, norepinephrine and Aβ peptides in Alzheimer's disease. Neurobiol. Stress 2015, 2:73-84.
45. Adolfsson R., et al. Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br. J. Psychiatry 1979, 135:216-223.
46. Gottfries C-G., et al. Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol. Aging 1984, 4:261-271.
47. Mann D., et al. The noradrenergic system in Alzheimer and multi-infarct dementias. J. Neurol. Neurosurg. Psychiatry 1982, 45:113-119.
48. Palmer A.M., et al. Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease. Brain Res. 1987, 401:231-238.
49. Reinikainen K.J., et al. A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease. J. Neurol. Sci. 1988, 84:101-116.
50. Kaddurah-Daouk R., et al. Metabolomic changes in autopsy-confirmed Alzheimer's disease. Alzheimers Dement. 2011, 7:309-317.
51. Czech C., et al. Metabolite profiling of Alzheimer's disease cerebrospinal fluid. PLoS ONE 2012, 7:10.
52. Elrod R., et al. Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. Am. J. Psychiatry 1997, 154:25-30.
53. Raskind M.A., et al. Norepinephrine and MHPG levels in CSF and plasma in Alzheimer's disease. Arch. Gen. Psychiatry 1984, 41:343-346.
54. Tohgi H., et al. Concentration of monoamines and their metabolites in the cerebrospinal fluid from patients with senile dementia of the Alzheimer type and vascular dementia of the Binswanger type. J. Neural Transm. Park. Dis. Dement. Sect. 1992, 4:69-77.
55. Wang L.Y., et al. Cerebrospinal fluid norepinephrine and cognition in subjects across the adult age span. Neurobiol. Aging 2013, 34:2287-2292.
56. Veening J.G., Barendregt H.P. The regulation of brain states by neuroactive substances distributed via the cerebrospinal fluid; a review. Cerebrospinal Fluid Res. 2010, 7. 10.1186/1743-8454-7-1.
57. Reiber H. Flow rate of cerebrospinal fluid (CSF) - a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J. Neurol. Sci. 1994, 122:189-203.
58. Lustig C., et al. Inhibitory deficit theory: recent developments in a 'new view'. The Place of Inhibition in Cognition 2007, 145-162. American Psychological Association. D.S. Gorfein, C.M. MacLeod (Eds.).
59. Prinz P., et al. Circadian variation of plasma catecholamines in young and old men: Relation to rapid eye movement and slow wave sleep. J. Clin. Endocrinol. Metab. 1979, 49:300-304.
60. Dobbs A.R., Rule B.G. Adult age differences in working memory. Psychol. Aging 1989, 4:500.
61. Arnsten A., et al. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J. Neurosci. 1988, 8:4287-4298.
62. Avery R.A., et al. The alpha-2A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task. Neuropsychopharmacology 2000, 23:240-249.
63. Meiran N., et al. Old age is associated with a pattern of relatively intact and relatively impaired task-set switching abilities. J. Gerontol. Ser. B Psychol. Sci. Soc. Sci. 2001, 56:P88-P102.
64. Rhodes M.G. Age-related differences in performance on the Wisconsin card sorting test: a meta-analytic review. Psychol. Aging 2004, 19:482.
65. Bouret S., Sara S.J. Network reset: a simplified overarching theory of locus coeruleus noradrenaline function. Trends Neurosci. 2005, 28:574-582.
66. Stark S.M., et al. Individual differences in spatial pattern separation performance associated with healthy aging in humans. Learn. Mem. 2010, 17:284-288.
67. Segal S.K., et al. Norepinephrine-mediated emotional arousal facilitates subsequent pattern separation. Neurobiol. Learn. Mem. 2012, 97:465-469.
68. Dickens W.T., Flynn J.R. Heritability estimates versus large environmental effects: the IQ paradox resolved. Psychol. Rev. 2001, 108:346.
69. Raizada R.D.S., Poldrack R.A. Challenge-driven attention: interacting frontal and brainstem systems. Front. Hum. Neurosci. 2008, 2:00000.
70. Naka F., et al. An enriched environment increases noradrenaline concentration in the mouse brain. Brain Res. 2002, 924:124-126.
71. Galani R., et al. The behavioral effects of enriched housing are not altered by serotonin depletion but enrichment alters hippocampal neurochemistry. Neurobiol. Learn. Mem. 2007, 88:1-10.
72. Rey N.L., et al. Behavioral and cellular markers of olfactory aging and their response to enrichment. Neurobiol. Aging 2012, 33:e9-e23.
73. Grilli M., et al. Exposure to an enriched environment selectively increases the functional response of the pre-synaptic NMDA receptors which modulate noradrenaline release in mouse hippocampus. J. Neurochem. 2009, 110:1598-1606.
74. Ramos B.P., Arnsten A.F.T. Adrenergic pharmacology and cognition: Focus on the prefrontal cortex. Pharmacol. Ther. 2007, 113:523-536.
75. Carlson M.C., et al. Exploring the effects of an 'everyday' activity program on executive function and memory in older adults: Experience Corps®. Gerontologist 2008, 48:793-801.
76. Park D.C., et al. The impact of sustained engagement on cognitive function in older adults: the synapse project. Psychol. Sci. 2014, 25:103-112.
77. Langa K.M. Is the risk of Alzheimer's disease and dementia declining?. Alzheimers Res. Ther. 2015, 7:34.
78. Larson E.B., et al. New insights into the dementia epidemic. N. Engl. J. Med. 2013, 369:2275-2277.
79. Brown B.S., et al. Chronic response of rat brain norepinephrine and serotonin levels to endurance training. J. Appl. Physiol. 1979, 46:19-23.
80. Gordon R., et al. Increased synthesis of norepinephrine and epinephrine in the intact rat during exercise and exposure to cold. J. Pharmacol. Exp. Ther. 1966, 153:440-447.
81. Ebrahimi S., et al. Central β-adrenergic receptors play an important role in the enhancing effect of voluntary exercise on learning and memory in rat. Behav. Brain Res. 2010, 208:189-193.
82. Van Hoomissen J.D., et al. Effects of β-adrenoreceptor blockade during chronic exercise on contextual fear conditioning and mRNA for galanin and brain-derived neurotrophic factor. Behav. Neurosci. 2004, 118:1378.
83. Segal S.K., et al. Exercise-induced noradrenergic activation enhances memory consolidation in both normal aging and patients with amnestic mild cognitive impairment. J. Alzheimers Dis. 2012, 32:1011-1018.
84. Bherer L., et al. A review of the effects of physical activity and exercise on cognitive and brain functions in older adults. J. Aging Res. 2013, 657508. 10.1155/2013/657508.
85. Mohs R.C., et al. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. Am. J. Geriatr. Psychiatry 2009, 17:752-759.
86. Starke K. Presynaptic autoreceptors in the third decade: focus on α2-adrenoceptors. J. Neurochem. 2001, 78:685-693.
87. Scullion G., et al. Chronic treatment with the α2-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APP× PS1 transgenic mice without altering β-amyloid plaque load or astrocytosis. Neuropharmacology 2011, 60:223-234.
88. Van Dyck C.H. Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects 2014, ClinicalTrials.gov.
89. Gu Q., et al. Prescription Drug Use Continues to Increase: U.S. Prescription Drug Data for 2007-2008 2010, NCHS Data Brief 42.
90. Hajjar I., et al. Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 2005, 60:67-73.
91. Paran E., et al. Cognitive function and antihypertensive treatment in the elderly: a 6-year follow-up study. Am. J. Ther. 2010, 17:358-364.
92. Prince M.J., et al. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's treatment trial of hypertension in older adults. BMJ 1996, 312:801-805.
93. Gliebus G., Lippa C.F. The influence of β-blockers on delayed memory function in people with cognitive impairment. Am. J. Alzheimers Dis. Other Dement. 2007, 22:57-61.
94. Braak H., Del Tredici K. Where, when, and in what form does sporadic Alzheimer's disease begin?. Curr. Opin. Neurol. 2012, 25:708-714.
95. German D.C., et al. Disease-specific patterns of locus coeruleus cell loss. Ann. Neurol. 1992, 32:667-676.
96. van Dongen P.A. The human locus coeruleus in neurology and psychiatry: Parkinson's, Lewy body, Hallervorden-Spatz, Alzheimer's and Korsakoff's disease, (pre) senile dementia, schizophrenia, affective disorders, psychosis. Prog. Neurobiol. 1981, 17:97-139.
97. Zarow C., et al. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 2003, 60:337-341.
98. Sanchez-Padilla J., et al. Mitochondrial oxidant stress in locus coeruleus is regulated by activity and nitric oxide synthase. Nat. Neurosci. 2014, 17:832-840.
99. Bekar L.K., et al. The locus coeruleus-norepinephrine network optimizes coupling of cerebral blood volume with oxygen demand. J. Cereb. Blood Flow Metab. 2012, 32:2135-2145.
100. Pamphlett R. Uptake of environmental toxicants by the locus ceruleus: A potential trigger for neurodegenerative, demyelinating and psychiatric disorders. Med. Hypotheses 2014, 82:97-104.
101. Finley K.H., Cobb S. The capillary bed of the locus coeruleus. J. Comp. Neurol. 1940, 73:49-58.
102. Braak H., Del Tredici K. The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. Brain 2015, 138:2814-2833.
103. Vohs K.D., Heatherton T.F. Self-regulatory failure: a resource-depletion approach. Psychol. Sci. 2000, 11:249-254.
104. Persson J., et al. Imaging fatigue of interference control reveals the neural basis of executive resource depletion. J. Cogn. Neurosci. 2013, 25:338-351.
105. Persson J., et al. Cognitive fatigue of executive processes: Interaction between interference resolution tasks. Neuropsychologia 2007, 45:1571-1579.
106. Bero A.W., et al. Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat. Neurosci. 2011, 14:750-756.
107. Choy R.W-Y., et al. Amyloid precursor protein (APP) traffics from the cell surface via endosomes for amyloid β (Aβ) production in the trans-Golgi network. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E2077-E2082.
108. Kamenetz F., et al. APP processing and synaptic function. Neuron 2003, 37:925-937.
109. Xie L., et al. Sleep drives metabolite clearance from the adult brain. Science 2013, 342:373-377.
110. Holroyd C.B. The waste disposal problem of effortful control. Motivation and Cognitive Control 2016, 235-260. Psychology Press. T. Braver (Ed.).
111. Jagust W.J., Mormino E.C. Lifespan brain activity, β-amyloid, and Alzheimer's disease. Trends Cog. Sci. 2011, 15:520-526.
112. Kang J-E., et al. Amyloid-β dynamics are regulated by orexin and the sleep-wake cycle. Science 2009, 326:1005-1007.
113. Iliff J.J., et al. Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine brain. J. Neurosci. 2013, 33:18190-18199.
114. Kong Y., et al. Norepinephrine promotes microglia to uptake and degrade amyloid β peptide through upregulation of mouse formyl peptide receptor 2 and induction of insulin-degrading enzyme. J. Neurosci. 2010, 30:11848-11857.
115. Koss M.C., et al. CNS adrenergic inhibition of parasympathetic oculomotor tone. J. Auton. Nerv. Syst. 1984, 10:55-68.
116. Wilhelm H. The pupil. Curr. Opin. Neurol. 2008, 21:36-42.
117. Joshi S., et al. Relationships between pupil diameter and neuronal activity in the locus coeruleus, colliculi, and cingulate cortex. Neuron 2015, 89:1-14.
118. Ishigaki H., et al. Change of pupil size as a function of exercise. J. Hum. Ergol. 1991, 20:61-66.
119. Nielsen S.E., Mather M. Comparison of two isometric handgrip protocols on sympathetic arousal in women. Physiol. Behav. 2015, 142:5-13.
120. Nielsen S.E., et al. Sympathetic arousal increases a negative memory bias in young women with low sex hormone levels. Psychoneuroendocrinology 2015, 62:96-106.
121. Bradley M.M., et al. Selective looking at natural scenes: hedonic content and gender. Int. J. Psychophysiol. 2015, 98:54-58.
122. Lowenstein O., Loewenfeld I.E. The sleep-waking cycle and pupillary activity. Ann. N. Y. Acad. Sci. 1964, 117:142-156.
123. Yoss R.E., et al. Pupil size and spontaneous pupillary waves associated with alertness, drowsiness, and sleep. Neurology 1970, 20:545.
124. Murphy P.R., et al. Pupil diameter covaries with BOLD activity in human locus coeruleus. Hum. Brain Mapp. 2014, 35:4140-4154.
125. Pfeifer M.A., et al. Differential changes of autonomic nervous system function with age in man. Am. J. Med. 1983, 75:249-258.
126. Winn B., et al. Factors affecting light-adapted pupil size in normal human subjects. Invest. Ophthalmol. Vis. Sci. 1994, 35:1132-1137.
127. Prettyman R., et al. Altered pupillary size and darkness and light reflexes in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 1997, 62:665-668.
128. Korczyn A.D., et al. Sympathetic pupillary tone in old age. Arch. Ophthalmol. 1976, 94:1905-1906.
129. Berridge C.W., Waterhouse B.D. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res. Rev. 2003, 42:33-84.
130. Lee T.H., et al. Emotional arousal amplifies the effects of biased competition in the brain. Soc. Cogn. Affect. Neurosci. 2014, 9:2067-2077.
131. Sakaki M., et al. Emotion strengthens high priority memory traces but weakens low priority memory traces. Psychol. Sci. 2014, 25:387-395.
132. Sutherland M.R., Mather M. Negative arousal amplifies the effects of saliency in short-term memory. Emotion 2012, 12:1367-1372.